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Abstract
Multiple endocrine neoplasia syndrome type 1 (MEN1) syndrome has benefited from the
identification of the gene whose mutations account for the genetic susceptibility to develop
endocrine tumors. Asymptomatic MEN1 mutant carriers need to be clearly recognized because the
gene-related mutations confer a high risk of multiple primary cancers, occur at younger ages, and
affect multiple family members who inherit the cancer-predisposing genetic mutation.
Introduction and context
Multiple endocrine neoplasia syndrome type 1 (MEN1)
syndrome is characterized by the occurrence of varying
combinations of more than 20 endocrine and non-
endocrine tumors. Endocrine tumors are represented
mainly by the ‘classic’ P-triad originally described by
Wermer: parathyroid, pituitary, and pancreatic tumors
[1-4]. Tables 1 and 2 describe the endocrine and non-
endocrine tumors associated with MEN1.
Familial and simplex MEN1 forms
The familial form of MEN1 syndrome occurs with a
significantly higher frequency (90% of cases) than the
simplex form, where only one individual is affected
within a family with no history of the disease (10% of
cases). Familial MEN1 is defined in an individual who
has at least one first-degree relative with one or more
main endocrine tumors or involvement of only one
organ and a MEN1 disease-causing germline mutation.
MEN1 syndrome is inherited in an autosomal dominant
manner, and each child of an affected individual has a
50% chance of inheriting the mutation [5].
Clinical definition of MEN1
MEN1 syndrome can be defined by the presence of two
‘classic’ endocrine tumors (parathyroid, pituitary, or
tumors of the gastro-entero-pancreatic tract) in an
affected subject. In Figure 1, an algorithmic summary
of the possible diagnostic scenario is presented.
Chromosomal location of the MEN1 gene
and related tumorigenesis
The MEN1 gene was originally located on chromosome
11q13 [6-8]. The related tumorigenesis was according to
Knudson’s ‘two hits’ hypothesis [9], strongly suggesting
a gene inactivation.
MEN1 gene and its mutations
The MEN1 gene spans 9 kb and consists of 10 exons with
a 1830-bp/1845-bp coding region encoding a novel 610/
615-amino acid protein (two isoforms [10]), referred to
as menin [11-13]. More than 1000 different germline
MEN1 mutations, without evidence of hot-spot regions,
have been described [14-18], mainly predicting absent or
truncated menin. Approximately 1-3% of MEN1 germ-
line mutations consist of large deletions detectable by
Southern blot analysis or other gene dosage procedures
(i.e., based on polymerase chain reaction) [15-18].
Polymorphic variants have also been described [18].
Neither the finding of a tumor suppressor mechanism
nor the identification of binding partners has established
the ultimate pathways of menin action in normal tissues
or in tumors [16].
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A DNA test of the MEN1 gene detects mutations in 80-
90% of probands with familial MEN1 and in 65% of
individuals with simplex MEN1 [18] (Table 3).
Genetic counseling in MEN1
Geneticcounselinghasacentralroleinthemanagementof
MEN1 patients and their closely related family members.
MEN1geneticallypredisposedsubjectsmaybenefitgreatly
from early identification by DNA analysis, especially at a
presymptomatic stage [15,17]. Once a pathogenic MEN1
mutation has been identified in a proband, referral to a
clinical geneticist is advised. Since it is recommended that
adequategeneticcounselingbegivenpriortoDNAtesting,
presymptomatic testing in families with an identified
MEN1 mutation should be performed within the context
of genetic counseling [19] (Tables 3 and 4).
Individuals at risk
Subjects in whom the germline mutation has not been
identified are at risk if they have inherited the MEN1
mutationfromoneaffectedparentoriftheyaretherelatives
of subjects clinically defined as suffering from MEN1.
Testing of relatives at risk
Genetic testing should be offered to at-risk members of a
family in which a germline MEN1 mutation has been
identified in an affected relative [18]. If molecular genetic
testing is not possible or is not informative, individuals
with a 50% risk (first-degree relatives of an individual
with MEN1 syndrome) should undergo routine evalua-
tion (Table 4). A DNA test for MEN1 may be offered to
children within their first decade because tumors such as
insulinoma and pituitary adenomas have developed in
some children by the age of 5 years [2,20,21] (Table 4).
Unfortunately, the great diversity and the lack of both
mutational hot-spots and genotype-phenotype correla-
tion make mutational screening time-consuming, ardu-
ous,andexpensive[14].Currently,aDNAtestidentifying
an individual as a mutant gene carrier does not usually
lead to immediate medical or surgical treatment, but it
does suggest that precocious and frequent clinical
screening should be carried out. Since we are still unable
to predict tumor penetrance and malignancy individu-
ally, lifelong follow-up of MEN1 carriers is strongly
recommended to prevent tumor morbidity.
Risk to family members
Approximately90%ofMEN1individualshaveanaffected
parent. However, the family history may appear negative
because of (a) failure to recognize the disorder in family
members, (b) early death of the parent before the onset of
symptoms, or (c) late onset of the disease in the affected
parent [17]. The risk to the siblings of the proband
dependsonthegeneticstatusoftheproband’spa re n ts .Ifa
parent of the proband is affected or has a disease-causing
Table 1. Multiple endocrine neoplasia syndrome type 1 (MEN1)-
related endocrine tumors and their prevalence (40 years)
Tumor type Tumor subtype Prevalence in MEN1
syndrome
Parathyroid
a Not applicable 100% by age 50 years
Anterior pituitary
(~10-60% of cases
have anterior pituitary
tumors)
Prolactinoma
(PRL-oma)
Most common anterior
pituitary tumor
Growth hormone-
secreting
5%
Growth hormone/
Prolactin-secreting
5%
TSH-secreting Rare
ACTH-secreting 2%
Well-differentiated
endocrine tumors
Gastrinoma
b 40%
Insulinoma 10%
Glucagonoma 2%
VIPoma 2%
Carcinoid
Bronchial 10%
Thymic
c
Adrenocortical (~20-
40% of cases have
adrenocortical
tumors)
Cortisol-secreting Rare
Aldosterone-secreting Rare
Pheochromocytoma <1%
aParathyroid tumors represent the main MEN1-associated endocrinopathy
whose onset, in 90% of individuals, is between the ages of 20 and 25 years
with hypercalcemia evident by the age of 50 years.
bThe MEN1
gastrinomas, located mainly at the duodenal level, are frequently multiple
and usually malignant, and half of them have metastasized before diagnosis.
cThymic carcinoids of MEN1 syndrome tend to be aggressive and are
highly lethal, particularly in male smokers [16]. Adrenocortical tumors are
rarely associated with primary hypercortisolism or hyperaldosteronism.
Among the non-endocrine tumors, facial angiofibromas, collagenomas,
lipomas, meningiomas, ependymomas, and leiomyomas have been
described in MEN1 subjects [16]. ACTH, adrenocorticotropic hormone;
PRL-oma, prolactin-secreting adenoma; TSH, thyroid-stimulating
hormone; VIPoma, vasoactive intestinal peptide-producing tumor.
Table 2. Multiple endocrine neoplasia syndrome type 1 (MEN1)-
related non-endocrine tumors and their prevalence (40 years)
Tumor type Tumor subtype Prevalence in MEN1
syndrome
Cutaneous tumors Lipomas 30%
Facial angiofibromas 85%
Collagenomas 70%
Central nervous
system
Meningiomas 5%
Ependymomas 1%
Other Leyomiomas 10%
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MEN1, multiple endocrine neoplasia syndrome type 1.
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causing mutation found in the proband cannot be
detected in the DNA of either parent, two possible
explanations exist: (a) germline mosaicism in a parent or
(b) a de novo mutation in the proband [17]. Each child of
an individual with MEN1 has a 50% chance of inheriting
the mutation. The risk to other family members depends
on the status of the proband’s parents. If a parent is found
to be affected or to have a disease-causing mutation or
both, his or her family members are at risk [17].
Families with an apparent de novo mutation
When neither parent of a proband with MEN1 has the
disease-causing mutation or clinical evidence of the
disorder, it is likely that the proband has a de novo
mutation (approximately 10%). However, explanations
such as alternate paternity or maternity (i.e., with
assisted reproduction), undisclosed adoption, or secre-
tiveness within the family could also be considered [17].
Testing of at-risk asymptomatic individuals
When a disease-causing germline mutation has been
identified in an affected family member, the genetic
testing of at-risk asymptomatic individuals is appropriate
for surveillance. When a known disease-causing muta-
tion is not identified, linkage or haplotype analysis can
be considered in families with more than one affected
family member from different generations. Early detec-
tion of at-risk individuals affects medical management,
and testing of asymptomatic individuals during child-
hood is beneficial [17].
Prenatal testing
Prenatal testing for MEN1 syndrome is not commonly
requested, partly due to the lack of a universal consensus
on performing such a diagnosis in MEN1. The disease-
causing allele of an affected family member must be
identified or linkage established in the family before
prenatal testing can be performed [17].
Detection of MEN1 gene mutations
The advantages of DNA analysis are that (a) it requires a
single blood sample and (b) it does not need to be
repeatedsincetheanalysis isindependentoftheage ofthe
individual and provides an objective result. Approxi-
mately 45% of germline mutations detected by sequence
analysis are small deletions, and approximately 15% are
small insertions [5]. The likelihood of detecting a MEN1
mutation is higher in individuals with more main P-triad
tumors, especially from families with hyperparathyroid-
ism and pancreatic islet tumors [22-24]. MEN1 genetic
screening should also be offered to patients with primary
hyperparathyroidism orgastrinomasafterthoroughinves-
tigation into the family history [25]. Simplex MEN1 cases
are less likely to test positive than familial cases, in part
because some of these simplex cases may be caused by
somatic mosaicism [24]. Individuals who have a single
MEN1-related tumor and no family history of MEN1
syndrome rarely have germline MEN1 mutations [22].
Recent advances
Intronic MEN1 mutations, such as SpaGVs (splicing-
affecting genomic variants), have been recently reported.
They are likely to be of significance in the 10% of MEN1
patients who do not have coding region mutations
[26,27]. A new intron 3 mutation associated with PRL-
oma (prolactin-secreting adenoma), decreased familial
penetrance, and variable effects on MEN1 mRNA and
menin have recently been described [28]. The MLPA
Table 3. General features of multiple endocrine neoplasia
syndrome type 1 (MEN1) predictive testing
 Diagnostic testing is appropriate in symptomatic individuals of any age.
 Confirming a diagnosis may alter medical management for the
individual.
 It is medically indicated since early diagnosis allows interventions that
reduce morbidity or mortality.
 Even in the absence of medical indications, predictive testing can
influence life planning decisions.
 Molecular genetic testing of an affected family member may be
required to determine the disease-causing mutation(s) present in the
family.
 Genetic testing should be offered to at-risk members of a family in
which a germline MEN1 mutation has been identified in an affected
relative. Identifying carriers allows reproductive choices.
 A DNA test in MEN1 may be offered to children within the first
decade because tumors such as insulinoma and pituitary adenomas
have developed in some children by the age of 5 years.
 Genetic counseling and education should accompany carrier testing
because of the potential for personal and social concerns.
 Many laboratories will not proceed with predictive testing without
proof of informed consent and genetic counseling.
 Identification of the specific gene mutation in an affected relative or
establishment of linkage within the family should precede predictive
testing.
 Because predictive testing can have psychological ramifications, careful
patient assessment, counseling, and follow-up are important.
 Predictive testing of asymptomatic children at risk for an adult-onset or
later-onset disorder is strongly discouraged when no medical
intervention is available (American Society of Human Genetics/
American College of Medical Genetics Policy Statement - 1995) [38].
 If molecular genetic testing is not possible or is not informative,
individuals at 50% risk (first-degree relatives of an individual with
MEN1 syndrome) should undergo routine biochemical-clinical
evaluation.
 Currently, a DNA test identifying an individual as a MEN1 mutant gene
carrier does not usually lead to immediate medical or surgical
treatment, but it suggests precocious and frequent clinical screening.
Table 4. Considerations when a multiple endocrine neoplasia
syndrome type 1 (MEN1) genetic test has to be ordered
The choosing of an adequate laboratory
Pretest counseling and appropriate informed consent
Sample logistics and supporting documentation
Test result interpretation and follow-up program
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assay may detect large deletions (4%) as germline
mutation in MEN1 [29]. Through polymorphism ana-
lyses, gene dose assays, and nucleotide sequencing, a
large germline deletion (approximately 29-kb pairs),
spanning the whole MEN1 gene, has been identified in
one patient with a positive family history for MEN1
whose germline MEN1 mutation was undetectable by
conventional sequencing analysis [30]. Moreover, geneti-
cally diagnosed patients already harbor manifestations at
the time of diagnosis, confirming that screening for a
MEN1 mutation should be done at an early age [31].
It is very important to consider that germline mutations
in other genes may cause a MEN1-like disorder in
MEN1 mutation-negative families, namely the AIP gene
[32] and the four cyclin-dependent kinase inhibitor
genes CDKN1A/p15, CDKN2C/p18, CDKN2B/p21, and
CDKN1B/p27 [33-35]. Interestingly, several of the
proteins encoded by these genes play a role within
the same molecular pathway as the menin protein.
Although germline mutations in these genes appear to
be rare (probably explaining only a small fraction of
the MEN1 mutation-negative families), it may still be
important to consider analysis of these genes in such
families.
Implications for clinical practice
MEN1 mutant gene carriers must be followed by periodic
clinical tumor surveillance as well as surveillance of
recurrence after treatment or progression of the disease.
The knowledge about carrier status enables early
diagnosis and intervention [2,17]. A prospective clinical
study on MEN1 mutant gene carriers revealed that
biochemical evidence of neoplasia could be identified
an average of 10 years before the clinical evidence of the
disease, allowing early surgery. Thus, genetically positive
individuals should undergo a focused surveillance for
early identification of potentially malignant neuroendo-
crine tumors accounting for morbidity and/or mortality
related to MEN1 [18].
Importantly, a very recent study having as the primary
endpoint the evaluation of the occurrence of non-
functioning pancreatic tumors (PETs) in asymptomatic
MEN1 children carriers revealed the presence of non-
functioning PETs, providing the opportunity to per-
form clinical surveillance to unravel their growth [36].
Thus, according to Triponez et al. [37], the possibility
of precociously identifying asymptomatic MEN1 chil-
dren carriers, as well as young adults with MEN1, may
be helpful for the early identification of non-function-
ing PETs that otherwise may not be biochemically
identified.
Gene testing decreased the morbidity and mortality
associated with MEN1
A multicenter study of more than 250 MEN1 gene
carriers revealed that, as a result of differential tumor
detection, MEN1 carriers born during the second half of
the 20th century tend to have their tumors diagnosed
earlier than carriers of the same age born in the first half
[31], a known general phenomen (anticipation phenom-
enon) observed in several other inherited tumors.
Conclusions
The identification of many molecular partners interacting
with menin has increased our knowledge of its patho-
physiology. However, more studies are necessary to
clarify the MEN1-dependent tumorigenesis and the role
that menin has in the development of endocrine and
non-endocrine tumors. In the near future, there are
prospects for novel treatments based on DNA, RNA, or
evenothersmallmolecules.Abetterunderstandingofthe
intricate molecular pathway networks related to menin
will be helpful for designing novel therapeutic strategies.
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MEN1, multiple endocrine neoplasia syndrome type 1;
PET, pancreatic tumor.
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